Method for diagnosing bone metastasis of malignant tumor

Details Method for diagnosing bone metastasis of malignant tumor Method for diagnosing bone metastasis of malignant tumor

1999-08-20

2009-12-15

Harris, Alana M (Department: 1643)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

Testing efficacy or toxicity of a compound or composition

C424S009100, C435S004000, C436S008000, C436S174000, C514S001000, C514S002600

Reexamination Certificate

active

07632486

ABSTRACT:
Bone metastasis and the efficacy of drugs in the treatment of malignant tumors such as breast cancer, prostatic cancer and lung cancer that cause the bone metastasis are diagnosed using a marker that reflects the activity of osteoblasts and a marker that reflects the action of osteoclasts.

REFERENCES:
Plebani et al. New and Traditional Serum Markers of Bone Metabolism in the Detection of Skeletal Metastases. Biochemistry 29(1):67-72, Feb. 1996.
Warrell. Gallium nitrate for the treatment of bone metastases. Cancer 80(8 Supplement): 1680-1685, 1997.
Martinetti et al. Serum Markers of bone metastases in postmenopausal breast cancer patients treated with formestane. Tumor Biol. 18: 197-205, 1997.
Koizumi et al. Bone metabolic markers in bone metastases. J Cancer Res Clin. Oncol. 121: 542-548, 1995.
Koizumi et al. Bone metabolic markers in bone metastasis of breast cancer. Int. J. Clin. Oncol. 4: 331-337, 1999.
Nakayama et al. Differences in Bone and Vitamin D Metabolism between Primary Hyperparathyroidism and Malignancy- Associated Hypercalcemia. Journal of Clinical Endocrinology and Metabolism 81(2): 607-611, 1996.
Tähtelä R and Thölix E. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res. Jul.-Aug., 1996;16(4B):2289-93. Abstract only.
Akimoto S et al. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Jpn J Clin Oncol. 26(3):157-63, Jun. 1996.
M. Koizumi, “Bone Metastasis of Cancer and Osteal Metabolism Marker”;Clinical Calcium, vol. 8, No. 4, May 1998; pp. 98-100, Only Abstract in English.
S. Takahashi et al.; “Significance of Osteal Metabolism Marker for Diagnosing Bone Metastasis”;Biotherapy, vol. 11, No. 1, pp. 75-80, 1997, Only Abstract in English.
K. Nakaba; “Correlation Among the Measurement of Therapeutic Effects on Bone Metastasis foci, Osteal Metabolism Marker and the Condition of Bone Metastasis”;Therapeutic Research, vol. 16, No. 12, pp. 212-217, 1995, Only Abstract in English.
Mitsuru Koizumi et al, “Bone Metabolic Markers in Bone Metastases”, J. Cancer Res. Clin. Oncol., V. 121, pp. 542-548, 1995.
Gary Stein et al, “Relationship of Cell Growth to the Regulation of Tissue-specific Gene Expression During Osteoblast Differentiation” The FASEB Journal, V. 4, pp. 3111-3123, Oct. 1990.
Patricia Ducy et al, “Increased Bone Formation in Osteocalcin-deficient Mice” Nature, V. 382; pp. 448-452, Aug. 1996.
Mona Calvo et al, “Molecular Basis and Clinical Application of Biological Markers of Bone Turnover”, Endocrine Reviews, v. 17, N. 4, pp. 333-368, 1996.
Mitsuru Koizumi and Etsuro Ogata, “Bone Metabolic Markers in Bone Metastasis”, The Bone, V. 10, N. 3, pp. 111-118, 1996.
M. Koizumi and E. Ogata, “Bone Metabolic Markers in Metastatic Bone Tumors” The Cancer Journal, vO1 11, N. 3, pp. 137-140, May-Jun. 1998.

Affiliated with

Also associated with

Rating

Method for diagnosing bone metastasis of malignant tumor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for diagnosing bone metastasis of malignant tumor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for diagnosing bone metastasis of malignant tumor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4087590